Clinical Trials Logo

Clinical Trial Summary

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy


Clinical Trial Description

Rationale: PSMA is a transmembrane protein, which is expressed on prostate cancers cells, ACC and other malignancies. In prostate cancer, distant metastases can be visualized sensitively and non-invasively with 68Ga-PSMA-PET/CT scans and if the uptake of 68Ga is high enough, patients can be treated with the β-emitting radionuclide 177Lu-PSMA. In the current study, we will evaluate the uptake of 68Ga-PSMA by performing 68Ga-PSMA-PET/CT scans in advanced ACC and SDC patients. If the uptake is high enough, this will form the rationale for a therapeutic study with 177Lu-PSMA in ACC and SDC.

Objective: The primary objective is to evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans. The secondary objectives are to calculate the SUV tumor-to-background ratio and tumor-to-'healthy salivary gland tissue' ratio. To correlate the SUV to the degree of immunohistochemical PSMA expression of the primary tumor on archival tissue, and to establish whether new metastatic lesions are found by 68GA-PSMA-PET/CT imaging.

Study design: Diagnostic study which evaluates the level of PSMA expression in ACC/SDC patients with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy.

Study population: Patients with locally advanced, recurrent or metastatic ACC/SDC of ≥18 years old. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03319641
Study type Interventional
Source Radboud University
Contact
Status Completed
Phase N/A
Start date October 25, 2017
Completion date May 14, 2018

See also
  Status Clinical Trial Phase
Completed NCT01417143 - Dovitinib in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT02978625 - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Phase 2
Not yet recruiting NCT03691207 - A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Phase 2
Recruiting NCT02942693 - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Phase 2
Completed NCT00581360 - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT03287427 - MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial Phase 1
Active, not recruiting NCT02775370 - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT02780310 - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Phase 2
Active, not recruiting NCT02098538 - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01524692 - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase 2
Completed NCT01558661 - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Recruiting NCT01192087 - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Phase 1/Phase 2
Recruiting NCT01586767 - Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy N/A
Completed NCT01152840 - Study of RAD001 in Adenoid Cystic Carcinoma Phase 2
Completed NCT00886132 - A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Phase 2
Recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03422679 - Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Phase 1/Phase 2
Completed NCT02662608 - Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) N/A
Active, not recruiting NCT03087019 - Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Phase 2